Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven W Johnson

Showing results (51-60 of 65) with videos related to

Pageof 7
Sort By:
Expert Opinion on Pharmacotherapy|September 21, 2013
Recent advances in the treatment of life-threatening, invasive fungal infectionsRichard H Drew, Mary L Townsend, Melanie W Pound, et al.
Therapeutics and Clinical Risk Management|August 19, 2016
Role of isavuconazole in the treatment of invasive fungal infectionsDustin T Wilson, V Paul Dimondi, Steven W Johnson, et al.
Psychopharmacology|March 14, 2009
The sigma-1 antagonist BMY-14802 inhibits L-DOPA-induced abnormal involuntary movements by a WAY-100635-sensitive mechanismMelanie A Paquette, Katherine Foley, Elizabeth G Brudney, et al.
Journal of Medicinal Chemistry|June 24, 2010
Platinum(II) complexes with bioactive carrier ligands having high affinity for the translocator proteinNicola Margiotta, Nunzio Denora, Rosa Ostuni, et al.
Cancer Biology & Therapy|September 26, 2003
Microarray data simulator for improved selection of differentially expressed genesSunil Singhal, Chris G Kyvernitis, Steven W Johnson, et al.
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|May 6, 2021
Evaluation of a risk assessment model to predict infection with healthcare facility-onset Clostridioides difficileCarrie S Tilton, Mary Elizabeth Sexton, Steven W Johnson, et al.
Neuropharmacology|January 19, 2010
MK-801 inhibits L-DOPA-induced abnormal involuntary movements only at doses that worsen parkinsonismMelanie A Paquette, Akari M Anderson, Jason R Lewis, et al.
Neuroreport|February 19, 2008
Sigma ligands, but not N-methyl-D-aspartate antagonists, reduce levodopa-induced dyskinesiasMelanie A Paquette, Elizabeth G Brudney, Daniel B Putterman, et al.
Pharmacy Practice|November 13, 2018
Evaluation of a vancomycin dosing nomogram in obese patients weighing at least 100 kilogramsRiley D Bowers, April A Cooper, Catherine L Wente, et al.
DNA and Cell Biology|March 7, 2002
Decreased expression of retinol-binding proteins is associated with malignant transformation of the ovarian surface epitheliumDavid Roberts, Stephen J Williams, Dusica Cvetkovic, et al.
Pageof 7

Showing results (51-60 of 65) with videos related to

Sort By:
Pageof 7
Expert Opinion on Pharmacotherapy|September 21, 2013
Recent advances in the treatment of life-threatening, invasive fungal infectionsRichard H Drew, Mary L Townsend, Melanie W Pound, et al.
Therapeutics and Clinical Risk Management|August 19, 2016
Role of isavuconazole in the treatment of invasive fungal infectionsDustin T Wilson, V Paul Dimondi, Steven W Johnson, et al.
Psychopharmacology|March 14, 2009
The sigma-1 antagonist BMY-14802 inhibits L-DOPA-induced abnormal involuntary movements by a WAY-100635-sensitive mechanismMelanie A Paquette, Katherine Foley, Elizabeth G Brudney, et al.
Journal of Medicinal Chemistry|June 24, 2010
Platinum(II) complexes with bioactive carrier ligands having high affinity for the translocator proteinNicola Margiotta, Nunzio Denora, Rosa Ostuni, et al.
Cancer Biology & Therapy|September 26, 2003
Microarray data simulator for improved selection of differentially expressed genesSunil Singhal, Chris G Kyvernitis, Steven W Johnson, et al.
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|May 6, 2021
Evaluation of a risk assessment model to predict infection with healthcare facility-onset Clostridioides difficileCarrie S Tilton, Mary Elizabeth Sexton, Steven W Johnson, et al.
Neuropharmacology|January 19, 2010
MK-801 inhibits L-DOPA-induced abnormal involuntary movements only at doses that worsen parkinsonismMelanie A Paquette, Akari M Anderson, Jason R Lewis, et al.
Neuroreport|February 19, 2008
Sigma ligands, but not N-methyl-D-aspartate antagonists, reduce levodopa-induced dyskinesiasMelanie A Paquette, Elizabeth G Brudney, Daniel B Putterman, et al.
Pharmacy Practice|November 13, 2018
Evaluation of a vancomycin dosing nomogram in obese patients weighing at least 100 kilogramsRiley D Bowers, April A Cooper, Catherine L Wente, et al.
DNA and Cell Biology|March 7, 2002
Decreased expression of retinol-binding proteins is associated with malignant transformation of the ovarian surface epitheliumDavid Roberts, Stephen J Williams, Dusica Cvetkovic, et al.
Pageof 7